Athersys (NASDAQ:ATHX) received a $6.00 price objective from investment analysts at Maxim Group in a research note issued on Tuesday, February 13th, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price objective suggests a potential upside of 328.57% from the company’s previous close.
Separately, ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd.
Athersys (NASDAQ:ATHX) opened at $1.40 on Tuesday. Athersys has a 12-month low of $1.08 and a 12-month high of $2.63. The company has a market capitalization of $170.54, a price-to-earnings ratio of -5.00 and a beta of -0.87.
In other news, COO William Lehmann, Jr. sold 14,000 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $1.80, for a total transaction of $25,200.00. Following the sale, the chief operating officer now directly owns 503,712 shares in the company, valued at $906,681.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 29,000 shares of company stock worth $51,075. Company insiders own 9.40% of the company’s stock.
Several institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its stake in shares of Athersys by 9.4% in the second quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock worth $6,441,000 after acquiring an additional 366,572 shares during the period. State Street Corp lifted its stake in shares of Athersys by 27.2% in the second quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock worth $2,161,000 after acquiring an additional 305,944 shares during the period. Northern Trust Corp lifted its stake in shares of Athersys by 30.8% in the second quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock worth $1,697,000 after acquiring an additional 264,549 shares during the period. Mckinley Capital Management LLC Delaware acquired a new position in shares of Athersys in the third quarter worth approximately $1,093,000. Finally, Royal Bank of Canada lifted its stake in shares of Athersys by 7,334.0% in the second quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock worth $576,000 after acquiring an additional 375,723 shares during the period. 19.45% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Athersys (ATHX) PT Set at $6.00 by Maxim Group” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/24/athersys-athx-pt-set-at-6-00-by-maxim-group.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.